NCT03145181 2026-03-12MajesTEC-1Janssen Research & Development, LLCPhase 1/2 Active not recruiting302 enrolled 1 FDA
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT04258943 2025-09-18Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid LeukemiaChildren's Oncology GroupPhase 1/2 Active not recruiting60 enrolled 1 FDA
NCT02500407 2025-09-12A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Genentech, Inc.Phase 1/2 Completed713 enrolled 1 FDA
NCT01915498 2024-10-22Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationCelgenePhase 1/2 Completed345 enrolled 120 charts 1 FDA
NCT02113982 2024-08-01Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaStemline Therapeutics, Inc.Phase 1/2 Completed138 enrolled 23 charts 1 FDA